Funding

Grants as principal applicant since 2000

2013-2016

Rosetrees Trust. Investigation of the role of chemokine signalling in retinal endothelial cells and its contribution to the development of retinal inflammatory conditions.
£107,208

2012-2013

University College London Business (UCLB), Proof of Concept Fund. (with S. Moss). The role of leucine-rich alpha-2-gycoprotein 1 (Lrg1) in cancer growth and metastasis.
£50,000

2011-2014

Fight for Sight (with S. Nourshargh). Molecular determinants of regional leukocyte traffic through the retinal vascular plexus.
£169,875

2011-2014

Rosetrees Trust/Impact studentship. The role of leucine-rich alpha-2-gycoprotein 1 in regulating retinal inflammatory disease.
£117,253 (£54,000 Rosetrees/£63,253 Impact)

2011-2014

Medical Research Council Developmental Pathway Funding Scheme (with S. Moss and J. Bainbridge). Development of a therapeutic antibody for a novel angiogenic target.
£759,418

2010-2013

Medical Research Council (with S. Moss and J. Bainbridge)
The role of leucine-rich alpha-2-glycoprotein in retinal vascular development and disease
£697,488

2010-2013

The Wellcome Trust (with S. Moss and J. Bainbridge)
The role of the apelin/APJ pathway in retinal vascular development and pathology
£295,334

2010-2013

The Wellcome Trust
Investigation of endothelial cell ICAM-1 signalling pathways and their role in controlling lymphocyte migration to the CNS
£290,139

2008-2010

Rosetrees Trust/Fight for Sight
Identifying new therapeutic targets and developing new treatments for retinal disease
£57,600

2007-2010

Moulton Charitable Foundation & Multiple Sclerosis Trials Collaboration (with V.Calder)
Immunomodulatory effect of long-term statin treatment in patients with secondary progressive multiple sclerosis
£126,483

2006-2009

Guide Dogs for the Blind Association (with P. Coffey and S. Moss)
Trans-differentiation of the human retinal pigment epithelial cell line ARPE-19 towards a photoreceptor phenotype: A potential cell for retinal repair
£162,970

2006-2009

Medical Research Council (with P. Turowski)
G-protein receptor signalling in CNS endothelial cells and its role in supporting lymphocyte migration
£460,000

2005-2010

The Lowy Medical Research Institute (Programme grant with S. Moss)
Vascular and RPE anomalies in idiopathic juxtafoveal telangiectasia
£881,000

2005-2009

European Union FP6 (with S. Moss)
Host retinal response to cellular therapy
£200,000

2002-2008

The Wellcome Trust (Programme Grant)
Investigation of endothelial mechanisms involved in facilitating leukocyte migration into the CNS
£701,829

2004-2007

Medical Research Council (with F. Fitzke, D. Keegan, J. Sinden and S. Moss)
Development of immortalised human foetal retinal progenitor stem cell lines for the treatment of retinal degeneration
£315,268

2004-2006

Merck Sharpe & Dohme (with P. Adamson and P. Turowski)
Development of immortalised rat brain endothelial cell lines
£131,930

2002-2005

The Multiple Sclerosis Society (with P. Adamson and D.Baker)
Therapeutic potential of pharmacological inhibition of brain endothelial cell signalling pathways controlling leukocyte migration into the CNS
£149,801

2000-2009

Joint Infrastructure Fund (Lead applicant with co-applicants S. Moss, P. Adamson, R. Ali, A. Bird, F. Fitzke, P. Khaw, P. Luthert and A. Webster)
Centre for the identification and development of novel treatment strategies for ocular disease
£9,200,000

2000-2003

The Wellcome Trust (with P. Coffey and R. Lund)
RPE transplantation in the RCS rat
£388,845

1998-2001

The Multiple Sclerosis Society (with P. Adamson)
Investigation of brain endothelial cell mechanisms controlling monocyte migration into the CNS: Identification of potential therapeutic targets
£128,601

1998-2000

ANVAR- (Demande d’aide a l’innovation. Grant from French Government) (with P. Couraud and P. Adamson)
Utilisation de lignées de cellules épithéliales pigmentaires rétiniennes en thérapie génique cellulaire de la dégénérescence maculaire liée à l’âge
4,000,000 FF (£400,000)

1997-2002

Neurotech S.A. (Programme grant with P. Adamson and R. Lund)
In vitro manufacture and in vivo assessment of immortalised human RPE cells and stealth RPE cells
£790,000